The drug will treat patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery.
The French drug maker, the third largest in the world, explained that the FDA grants priority review to products that, if approved, would be a significant improvement compared to marketed products, including non-drug products in the treatment, diagnosis or prevention of a disease.
To date, Taxotere has received a total of seven indications in the US.